Comprehensive Neuromuscular Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Comprehensive Neuromuscular Program. Real-time updates on events, politics, business and more.

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial

February 29, 2024

Company to host webcast on Tuesday, March 5, 2024 at 8:30 a.m. ESTInterim clinical data will be presented by Aravindhan Veerapandiyan, M.D., primary investigator of the AFFINITY DUCHENNE trial, at...

United States Aravindhan Veerapandiyan Dana Cormack Chris Brinzey Muscular Dystrophy Association Certified Duchenne Care Center

Source: marketscreener.com

REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients

January 23, 2023

- Company has initiated Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 - Company also enrolling newly active observational screening study, AFFINITY BEYOND,...

United States Dana Cormack Aravindhan Veerapandiyan Chris Brinzey Technology Platform Technology Platform Licensees

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Comprehensive Neuromuscular Program News Today

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE&#xAE; Trial

REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients

Explore More Categories

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial